These authors suggest that elevated levels of bcl-2 in CD4+ T cells from MS patients result from decreased levels of miR-15a and miR-16-1, which target this potent anti-apoptotic gene (Lorenzi et al., 2012). The gene discussed is CD4; the disease is myeloid sarcoma.